Elisabeth Kemter1, Joachim Denner2, Eckhard Wolf3,4. 1. Gene Center, and Center for Innovative Medical Models (CiMM), LMU Munich, Feodor-Lynen-Str. 25, 81377, Munich, Germany. 2. Robert Koch Institute, Nordufer 20, 13353, Berlin, Germany. 3. Gene Center, and Center for Innovative Medical Models (CiMM), LMU Munich, Feodor-Lynen-Str. 25, 81377, Munich, Germany. ewolf@genzentrum.lmu.de. 4. German Center for Diabetes Research (DZD), Neuherberg, Germany. ewolf@genzentrum.lmu.de.
Abstract
PURPOSE OF REVIEW: Porcine islets represent a potentially attractive beta-cell source for xenotransplantation into patients with type 1 diabetes, who are not eligible to islet allo-transplantation due to a lack of suitable human donor organs. Recent progress in genetic engineering/gene editing of donor pigs provides new opportunities to overcome rejection of xeno-islets, to improve their engraftment and insulin secretion capacity, and to reduce the risk for transmission of porcine endogenous retroviruses. This review summarizes the current issues and progress in islet xenotransplantation with special emphasis on genetically modified/gene edited donor pigs. RECENT FINDINGS: Attempts to overcome acute rejection of xeno-islets, especially after intraportal transplantation into the liver, include the genetic elimination of specific carbohydrate antigens such as αGal, Neu5Gc, and Sd(a) for which humans and-in part-non-human primates have natural antibodies that bind to these targets leading to activation of complement and coagulation. A complementary approach is the expression of one or more human complement regulatory proteins (hCD46, hCD55, hCD59). Transgenic attempts to overcome cellular rejection of islet xenotransplants include the expression of proteins that inhibit co-stimulation of T cells. Expression of glucagon-like peptide-1 and M3 muscarinic receptors has been shown to increase the insulin secretion of virally transduced porcine islets in vitro and it will be interesting to see the effects of these modifications in transgenic pigs and islet products derived from them. Genome-wide inactivation of porcine endogenous retrovirus (PERV) integrants by mutating their pol genes using CRISPR/Cas9 is a recent approach to reduce the risk for PERV transmission by xeno-islets. Genetic engineering/gene editing of xeno-islet donor pigs facilitated major progress towards clinical islet xenotransplantation. The required set of genetic modifications will depend on the source of islets (fetal/neonatal vs. adult), the mode of delivery (encapsulated vs. free), and the transplantation site.
PURPOSE OF REVIEW: Porcine islets represent a potentially attractive beta-cell source for xenotransplantation into patients with type 1 diabetes, who are not eligible to islet allo-transplantation due to a lack of suitable humandonor organs. Recent progress in genetic engineering/gene editing of donorpigs provides new opportunities to overcome rejection of xeno-islets, to improve their engraftment and insulin secretion capacity, and to reduce the risk for transmission of porcine endogenous retroviruses. This review summarizes the current issues and progress in islet xenotransplantation with special emphasis on genetically modified/gene edited donorpigs. RECENT FINDINGS: Attempts to overcome acute rejection of xeno-islets, especially after intraportal transplantation into the liver, include the genetic elimination of specific carbohydrate antigens such as αGal, Neu5Gc, and Sd(a) for which humans and-in part-non-human primates have natural antibodies that bind to these targets leading to activation of complement and coagulation. A complementary approach is the expression of one or more human complement regulatory proteins (hCD46, hCD55, hCD59). Transgenic attempts to overcome cellular rejection of islet xenotransplants include the expression of proteins that inhibit co-stimulation of T cells. Expression of glucagon-like peptide-1 and M3 muscarinic receptors has been shown to increase the insulin secretion of virally transduced porcine islets in vitro and it will be interesting to see the effects of these modifications in transgenic pigs and islet products derived from them. Genome-wide inactivation of porcine endogenous retrovirus (PERV) integrants by mutating their pol genes using CRISPR/Cas9 is a recent approach to reduce the risk for PERV transmission by xeno-islets. Genetic engineering/gene editing of xeno-islet donorpigs facilitated major progress towards clinical islet xenotransplantation. The required set of genetic modifications will depend on the source of islets (fetal/neonatal vs. adult), the mode of delivery (encapsulated vs. free), and the transplantation site.
Authors: Jose L Estrada; Greg Martens; Ping Li; Andrew Adams; Kenneth A Newell; Mandy L Ford; James R Butler; Richard Sidner; Matt Tector; Joseph Tector Journal: Xenotransplantation Date: 2015-03-01 Impact factor: 3.907
Authors: P Thompson; I R Badell; M Lowe; J Cano; M Song; F Leopardi; J Avila; R Ruhil; E Strobert; G Korbutt; G Rayat; R Rajotte; N Iwakoshi; C P Larsen; A D Kirk Journal: Am J Transplant Date: 2011-08-29 Impact factor: 8.086
Authors: Qimeng Gao; Robert Davis; Zachary Fitch; Michael Mulvihill; Brian Ezekian; Paul Schroder; Robin Schmitz; Mingqing Song; Frank Leopardi; Marianna Ribeiro; Allison Miller; Dimitrios Moris; Brian Shaw; Kannan Samy; Keith Reimann; Kyha Williams; Bradley Collins; Allan D Kirk Journal: Xenotransplantation Date: 2021-11 Impact factor: 3.907
Authors: Cataldo Pignatelli; Francesco Campo; Alessia Neroni; Lorenzo Piemonti; Antonio Citro Journal: Transpl Int Date: 2022-08-25 Impact factor: 3.842